THPP-1

CAS No. 1257051-63-0

THPP-1( —— )

Catalog No. M22050 CAS No. 1257051-63-0

THPP-1 is a potent and orally bioavailable inhibitor of PDE10A(Ki of 1 nM and 1.3 nM for human and rat PDE10A, respectively).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 40 Get Quote
5MG 65 Get Quote
10MG 110 Get Quote
25MG 237 Get Quote
50MG 402 Get Quote
100MG 593 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    THPP-1
  • Note
    Research use only, not for human use.
  • Brief Description
    THPP-1 is a potent and orally bioavailable inhibitor of PDE10A(Ki of 1 nM and 1.3 nM for human and rat PDE10A, respectively).
  • Description
    THPP-1 is a potent and orally bioavailable inhibitor of PDE10A(Ki of 1 nM and 1.3 nM for human and rat PDE10A, respectively). Consistent with rodent data, both THPP-1 and risperidone significantly attenuated the stimulant effects in SIMA when administered alone, though some differences were noted.?Combination therapy with a low dose of risperidone produced significantly more robust effects.?THPP-1 and risperidone also produced a marked reduction of wake cycle time and gamma frequency power in EEG.?However, THPP-1 differed from risperidone by reducing spectral power of lower frequencies.
  • In Vitro
    ——
  • In Vivo
    THPP-1 (0.1-1.0 mg/kg, p.o.) shows novel object recognition in rats.THPP-1 (p.o., 1-30 mg/kg) dose-dependently increases phosphorylation of GluR1 S845 in the rat striatum whereas the total levels of GluR1 in the striatum are not affected. Administration of THPP-1 also results in an associated increase in the pGluR1/GluR1 ratios at all doses examined in this study.THPP-1 (1, 3, 10 mg/kg, p.o.) significantly attenuated the stimulant effects in stimulant-induced motor activity (SIMA) in monkey. Animal Model:Male Wistar Hannover rats ranging from 200 to 300 g.Dosage:0.1-1.0 mg/kg.Administration:P.O.Result:Showed novel object recognition.Animal Model:Eleven monkeys were surgically implanted with subcutaneous telemetric devices to permit the simultaneous recording of electrocorticogram (ECoG), electrooculogram (EOG), and electromyogram (EMG) activit Dosage:1, 3, 10 mg/kg. Administration:P.O.Result:Significantly attenuated the stimulant effects in SIMA.Animal Model:Male Wistar Hannover rats ranging from 200 to 300 g.Dosage:1-30 mg/kg.Administration:P.O. (10% Tween 80/90% water) 2 h prior to tissue collection (Pharmacokinetic Analysis).Result:Dose-dependently increases phosphorylation of GluR1 S845.
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    PDE
  • Recptor
    PDE10A
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1257051-63-0
  • Formula Weight
    464.9
  • Molecular Formula
    C23H21ClN6O3
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:31 mg/mL (66.68 mM; Need ultrasonic)
  • SMILES
    COCCOC1=C2CN(CCC2=NC(=N1)C1=CC=C(Cl)N=C1)C(=O)C1=C2C=CC=CN2C=N1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Vardigan JD, et al. Behavioral and qEEG effects of the PDE10A inhibitor THPP-1 in a novel rhesus model of antipsychotic activity. Psychopharmacology (Berl). 2016 Jul;233(13):2441-50.
molnova catalog
related products
  • HA-155

    HA155 is a boronic acid-based compound, inhibiting ATX with IC50 of 5.7 nM by selectively binding to its catalytic threonine.

  • ONO-8430506

    ONO-8430506 is an orally available, potent autotaxin (ATX)/ENPP2 inhibitor (IC90: 100 nM) that inhibits ATX activity in mouse plasma.

  • (+)-Medioresinol Di-...

    (+)-Medioresinol Di-O-β-D-glucopyranoside has strong inhibitory activity of cyclic AMP phosphodiesterase.